Technology
Health
Biotechnology

SELLAS Life Sciences

$1.38
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-11.45%) Today
+$0.22 (18.97%) After Hours

Why Robinhood?

You can buy or sell SLS and other stocks, options, ETFs, and crypto commission-free!

About

SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. Read More The company was founded on April 3, 2006 and is headquartered in New York, NY.

Employees
11
Headquarters
New York, New York
Founded
2006
Market Cap
26.86M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
913.57K
High Today
$1.29
Low Today
$1.13
Open Price
$1.22
Volume
582.07K
52 Week High
$11.09
52 Week Low
$0.8001

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
Biopharmaceutical
Pharmaceutical
US

News

Markets Insider12h

SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update

NEW YORK, March 22, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today reported financial results for the year ended December 31, 2018 and provided a business update. “In February, we initiated a review of a wide range of strategic alternatives to maximize shareholder value, such as a sale of the Company, a m...

176
BenzingaFeb 26

Sellas (NASDAQ:SLS) Reviews Strategic Options To Fund Clinical Development Programs

Cancer immunotherapy company Sellas Life Sciences Group Inc (NASDAQ: SLS) announced Tuesday that its board is conducting a review of strategic options in a bid to maximize shareholder value.

188

Earnings

Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.